These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

384 related items for PubMed ID: 27193833

  • 1. Suppression of KRas-mutant cancer through the combined inhibition of KRAS with PLK1 and ROCK.
    Wang J, Hu K, Guo J, Cheng F, Lv J, Jiang W, Lu W, Liu J, Pang X, Liu M.
    Nat Commun; 2016 May 19; 7():11363. PubMed ID: 27193833
    [Abstract] [Full Text] [Related]

  • 2. A combination therapy for KRAS-mutant lung cancer by targeting synthetic lethal partners of mutant KRAS.
    Pang X, Liu M.
    Chin J Cancer; 2016 Oct 28; 35(1):92. PubMed ID: 27793187
    [Abstract] [Full Text] [Related]

  • 3. Suppression of Polo like kinase 1 (PLK1) by p21(Waf1) mediates the p53-dependent prevention of caspase-independent mitotic death.
    Lin YC, Sun SH, Wang FF.
    Cell Signal; 2011 Nov 28; 23(11):1816-23. PubMed ID: 21726628
    [Abstract] [Full Text] [Related]

  • 4. Long-term downregulation of Polo-like kinase 1 increases the cyclin-dependent kinase inhibitor p21(WAF1/CIP1).
    Kreis NN, Sommer K, Sanhaji M, Krämer A, Matthess Y, Kaufmann M, Strebhardt K, Yuan J.
    Cell Cycle; 2009 Feb 01; 8(3):460-72. PubMed ID: 19177004
    [Abstract] [Full Text] [Related]

  • 5. The GTPase KRAS suppresses the p53 tumor suppressor by activating the NRF2-regulated antioxidant defense system in cancer cells.
    Yang H, Xiang S, Kazi A, Sebti SM.
    J Biol Chem; 2020 Mar 06; 295(10):3055-3063. PubMed ID: 32001619
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Synergistic effects of FGFR1 and PLK1 inhibitors target a metabolic liability in KRAS-mutant cancer.
    Yang Z, Liang SQ, Saliakoura M, Yang H, Vassella E, Konstantinidou G, Tschan M, Hegedüs B, Zhao L, Gao Y, Xu D, Deng H, Marti TM, Kocher GJ, Wang W, Schmid RA, Peng RW.
    EMBO Mol Med; 2021 Sep 07; 13(9):e13193. PubMed ID: 34369083
    [Abstract] [Full Text] [Related]

  • 11. Inhibition of polo-like kinase 1 leads to the suppression of osteosarcoma cell growth in vitro and in vivo.
    Liu X, Choy E, Harmon D, Yang S, Yang C, Mankin H, Hornicek FJ, Duan Z.
    Anticancer Drugs; 2011 Jun 07; 22(5):444-53. PubMed ID: 21399492
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Indirect p53-dependent transcriptional repression of Survivin, CDC25C, and PLK1 genes requires the cyclin-dependent kinase inhibitor p21/CDKN1A and CDE/CHR promoter sites binding the DREAM complex.
    Fischer M, Quaas M, Nickel A, Engeland K.
    Oncotarget; 2015 Dec 08; 6(39):41402-17. PubMed ID: 26595675
    [Abstract] [Full Text] [Related]

  • 16. p53-dependent repression of polo-like kinase-1 (PLK1).
    McKenzie L, King S, Marcar L, Nicol S, Dias SS, Schumm K, Robertson P, Bourdon JC, Perkins N, Fuller-Pace F, Meek DW.
    Cell Cycle; 2010 Oct 15; 9(20):4200-12. PubMed ID: 20962589
    [Abstract] [Full Text] [Related]

  • 17. Induction of p21(Waf1/Cip1) by garcinol via downregulation of p38-MAPK signaling in p53-independent H1299 lung cancer.
    Yu SY, Liao CH, Chien MH, Tsai TY, Lin JK, Weng MS.
    J Agric Food Chem; 2014 Mar 05; 62(9):2085-95. PubMed ID: 24533688
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Mutations of the LIM protein AJUBA mediate sensitivity of head and neck squamous cell carcinoma to treatment with cell-cycle inhibitors.
    Zhang M, Singh R, Peng S, Mazumdar T, Sambandam V, Shen L, Tong P, Li L, Kalu NN, Pickering CR, Frederick M, Myers JN, Wang J, Johnson FM.
    Cancer Lett; 2017 Apr 28; 392():71-82. PubMed ID: 28126323
    [Abstract] [Full Text] [Related]

  • 20. Phosphorylation of FADD by the kinase CK1α promotes KRASG12D-induced lung cancer.
    Bowman BM, Sebolt KA, Hoff BA, Boes JL, Daniels DL, Heist KA, Galbán CJ, Patel RM, Zhang J, Beer DG, Ross BD, Rehemtulla A, Galbán S.
    Sci Signal; 2015 Jan 27; 8(361):ra9. PubMed ID: 25628462
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.